MTOR and cancer: The inability to correlate the differential localization of pAKT Ser473 with clinicopathological parameters or disease-free survival in our study, with samples showing prevalent cytoplasmic labeling (HR = 2.63; Cox p = 0.2; n = 41) and others displaying prevalent nuclear labeling (HR = 1.29; Cox p = 0.8; n = 41), highlights the complexity of the PI3K/AKT/mTOR signaling pathway and the diverse mechanisms that contribute to its activation in cancer.